Article citationsMore>>

Joensuu, H., Eriksson, M., Hatrmann, J., et al. (2011) Twelve versus 36 Months of Adjuvant Imatinib (IM) as Treatment of Operable GIST with a High Risk of Recurrence: Final Results of a Randomized Trial (SSGXVIII/AIO). Journal of Clinical Oncology, 29, No. 18.
https://doi.org/10.1200/jco.2011.29.18_suppl.lba1

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top